CN113575928A - Health food composition rich in plant polyphenol and sterol - Google Patents

Health food composition rich in plant polyphenol and sterol Download PDF

Info

Publication number
CN113575928A
CN113575928A CN202010362704.9A CN202010362704A CN113575928A CN 113575928 A CN113575928 A CN 113575928A CN 202010362704 A CN202010362704 A CN 202010362704A CN 113575928 A CN113575928 A CN 113575928A
Authority
CN
China
Prior art keywords
parts
weight
buckwheat
health food
food composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010362704.9A
Other languages
Chinese (zh)
Inventor
刘庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Yaoshi Congyuan Trading Co ltd
Original Assignee
Beijing Yaoshi Congyuan Trading Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Yaoshi Congyuan Trading Co ltd filed Critical Beijing Yaoshi Congyuan Trading Co ltd
Priority to CN202010362704.9A priority Critical patent/CN113575928A/en
Publication of CN113575928A publication Critical patent/CN113575928A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/115—Cereal fibre products, e.g. bran, husk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/152—Cereal germ products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention relates to a health food composition, which consists of grains rich in plant polyphenol and sterol, traditional Chinese medicines and yeast, wherein the grains are one or more of quinoa, oat, buckwheat, highland barley, buckwheat bran and buckwheat germ, and the traditional Chinese medicines are one or two of rhizoma polygonati and radix puerariae. The invention exerts the synergistic hypoglycemic effect through the comprehensive action of various bioactive substance groups, and the synergistic effect of multi-level, multi-target and multi-angle such as polyphenol, sterol, dietary fiber, protein, polypeptide, oligopeptide, beta-glucan, flavone, D-chiral inositol, ecdysone and the like is realized, thereby showing excellent effect in the hypoglycemic experiment and clinical experiment of mice.

Description

Health food composition rich in plant polyphenol and sterol
Technical Field
The invention belongs to the field of health food, and particularly relates to a health food composition rich in plant polyphenol and sterol.
Background
According to the statistics of the international diabetes association, the number of diabetes patients is over 4.15 hundred million in the whole world in 2015, and the number of diabetes patients is predicted to reach 6.42 hundred million in 2040 years, so that the prevention and treatment of diabetes are in the forefront. The western medicine has great side effect and poor curative effect. The traditional Chinese medicine has unique advantages in treating diabetes, applies the concept of 'preventive treatment of disease' and the theory of 'homology of medicine and food' of traditional Chinese medicine to the prevention and treatment of diabetes, and is an important way for delaying the occurrence and development of diabetes. In the clinical prevention and treatment of diabetes, the key is diet therapy throughout the disease. The traditional Chinese medicine has a diet since ancient times since the treatment of disease and a medicated diet since the treatment of disease. How to apply food with nutrition and drug effect to the prevention and treatment of diabetes is one of the most important research subjects in the current society.
Plant polyphenols contained in grains and chinese medicines are known to be useful for improving diabetes. Typical representatives of such plant polyphenols are flavonoids, such as Quercetin (Quercetin, 3,3',4',5, 7-pentahydroxyflavone). Quercetin can significantly improve hyperglycemia, hypertriglyceridemia and hypercholesterolemia of diabetic mice induced by streptozotocin, and the mechanism of quercetin is probably related to effectively removing free radicals in vivo and relieving injury caused by oxidative stress. Quercetin also reduces inflammatory response and lipid accumulation in liver under hyperglycemia, stimulates glucose transporter 4(GLUT4) in skeletal muscle to perform translocation reaction, and inhibits activity of glucose-6-phosphatase in liver cell to maintain glucose homeostasis in vivo. Can effectively reduce the insulin resistance of rats and inhibit the pathological damage of pancreatic tissues and islet cells, and the action mechanism of the insulin resistance can be related to the activation of FGF21/AMPK signal pathways in the pancreatic tissues.
Phytosterols are also beneficial in the amelioration of diabetes. In vitro experiments, treatment of L6 cells (skeletal muscle cell model of insulin resistance) with stigmasterol at various concentrations had a significant effect in promoting glucose uptake. Stigmasterol can prevent free cholesterol and active oxygen level increase caused by glucotoxicity in INS-1 cell (rat islet cell tumor), inhibit early apoptosis, increase total insulin, promote actin recombination, and improve insulin secretion of glucotoxic cell. In an in vivo test, after the stigmasterol is orally taken, the fasting blood glucose level of KK-AY mice is obviously reduced, and the insulin resistance and the oral glucose tolerance of the KK-AY mice are obviously reduced. The mechanism may be associated with increased translocation and expression of GLUT4, suggesting that stigmasterol has potential benefits for the treatment of type 2 diabetes. Studies show that stigmasterol can improve insulin secretion and increase insulin content by preventing accumulation of free cholesterol and active oxygen and protecting pancreatic beta cells. In addition, the hypoglycemic effect of sitosterol is also reported. In an oral glucose tolerance experiment, the beta-sitosterol and the glucoside thereof can improve the fasting plasma insulin level and reduce the fasting blood glucose, and the beta-sitosterol glucoside has better effect than the beta-sitosterol. In streptozotocin-induced diabetes mellitus models in rats, after various groups take beta-sitosterol orally, the insulin release is increased through antioxidant activity or beta-cell regeneration, the insulin promoting effect of the sitosterol is enhanced, and the blood sugar and the glycosylated hemoglobin level can be reduced.
Despite the above reports, there are still no multi-level, multi-target, multi-angle systematic studies on plant effective ingredients, and no overall studies on complex components, and the relationship between different types of components, such as the synergistic effect of cereals and traditional Chinese medicinal materials, is rather short of corresponding studies.
Disclosure of Invention
The invention aims to provide a health food composition rich in plant polyphenol and sterol.
It is a further object of the present invention to provide a health food composition rich in a plurality of effective components such as plant polyphenols, sterols, dietary fibers, β -glucan and the like.
It is a further object of the present invention to provide a health food composition which has a beneficial effect on the improvement of diabetes.
It is a further object of the present invention to provide a health food composition which can assist in lowering blood glucose.
The invention aims to realize the technical scheme that the health food composition consists of grains rich in plant polyphenol and sterol, traditional Chinese medicines and optionally yeast.
In a preferred embodiment, the grain is one or more of quinoa, oat, buckwheat, highland barley, buckwheat bran, and buckwheat germ.
As a preferred embodiment, the traditional Chinese medicine is one or two of rhizoma polygonati and radix puerariae.
In a preferred embodiment, the grains comprise 30-60 parts by weight of quinoa, 10-20 parts by weight of oat, 10-20 parts by weight of buckwheat bran and 5-10 parts by weight of buckwheat germ.
As a preferred embodiment, the traditional Chinese medicine is 2-5 parts by weight of rhizoma polygonati, 2-5 parts by weight of radix puerariae, and optionally 1-2 parts by weight of yeast.
As a preferred embodiment, the health food composition comprises 30-60 parts by weight of quinoa, 10-20 parts by weight of oat, 2-5 parts by weight of polygonatum sibiricum, 2-5 parts by weight of pueraria lobata, and optionally 1-2 parts by weight of yeast.
As a preferred embodiment, the health food composition comprises 30-50 parts by weight of quinoa, 10-20 parts by weight of highland barley, 10-20 parts by weight of oat, 10-20 parts by weight of buckwheat, 5-10 parts by weight of buckwheat bran, 5-10 parts by weight of buckwheat germ, 2-5 parts by weight of polygonatum sibiricum, 2-5 parts by weight of kudzu root, and optionally 1-2 parts by weight of yeast.
As a preferred embodiment, the above health food composition is used for improving diabetes, or for assisting in lowering blood sugar.
In a preferred embodiment, the health food composition is used for lowering blood glucose and increasing fasting blood insulin level.
As a preferred embodiment, the above health food composition is used for preparing a health food for improving diabetes or assisting in lowering blood glucose.
As a preferred embodiment, the health food may be in various forms such as powder, biscuit, cake, noodle, steamed bread, etc.
The quinoa is a low-fructose and low-glucose food, and can play a beneficial role in the glycolipid metabolism process. Quinoa is rich in polyphenols: the average yield of quinoa polyphenol is (226.77 + -1.94) mg/100g by performing 3 parallel experiments under the conditions of ethanol concentration of 49%, feed-liquid ratio of 1: 26(g/mL), extraction temperature of 73 deg.C and extraction time of 62 min. The extraction amount of polyphenol was found to be 2.273mg/g under the extraction conditions of 56% ethanol volume fraction, 84 ℃ extraction temperature and 1: 40 feed-liquid ratio. Extracting with 70% ethanol at a ratio of 1: 25(g/mL) under ultrasonic wave of 320W for 20min to obtain quinoa polyphenol with yield of 0.215%. Ultrasonic oscillation is adopted, the extraction time is 23min, the volume fraction of ethanol is 71%, the material-liquid ratio is 1: 23(g/mL), the extraction temperature is 52 ℃, and the extraction amount of polyphenol is 3.33 mg/g. The quinoa malt is extracted with 53% ethanol under shaking at a material-liquid ratio of 1: 28.5(g/mL), an extraction temperature of 69 deg.C and an extraction time of 115min, and under the process conditions, the polyphenol yield is 224mg/100 g. In addition, the dietary fiber as a non-starch polysaccharide is rich in quinoa, the quinoa dietary fiber mainly comprises pectin polysaccharide and xylan which are rich in arabinose, the insoluble fiber comprises galacturonic acid, galactose, xylose and glucose, and contains galacturonic acid polysaccharide, rhamnogalacturonan (55-60%) containing arabinosan side chains, highly branched xylan (30%) and cellulose; the soluble fiber comprises glucose, galacturonic acid and arabinose, quinoa is a low fructose glucose index food and can regulate glycolipid metabolism, and non-starch polysaccharide in quinoa is a main active ingredient for reducing blood lipid. Ecdysone is a secondary metabolite in a steroid form found in quinoa seeds, wherein 20-hydroxyecdysone (20E) is the main phytoecdysteroid substance in plants, and bran is found in quinoa seeds to have the highest content, so that the effects of reducing blood sugar, inhibiting obesity and the like are better. Quinoa is rich in various mineral substances such as Mn, Fe, Mg, Ca, K, Se, Cu, P, Zn and the like, and the mineral element content of quinoa is higher than that of common grains. The beta-glucosidase promotes the cellulose degradation and the utilization of glucose, Mn2+ and Co2+ are beta-glucosidase activators, and the beta-glucosidase activity can be improved and the blood sugar level can be reduced by ingesting quinoa. In-vitro enzyme inhibition experiments show that phenols and flavonoids in quinoa can inhibit alpha-glucosidase in digestive system, so that the compounds have potential blood sugar reducing effect, are particularly suitable for type 2 diabetes patients, and can be potentially developed into staple food for diabetes people.
The oat bran is rich in polyphenol, and the oat bran polyphenol can reduce fasting blood glucose value of type 2 diabetic mice caused by alloxan, promote insulin secretion, protect immune organs of an organism, enhance oxidation resistance of the organism and promote glycolipid metabolism. The oat beta-glucan can also inhibit the action of sucrase, lactase and maltase in the intestinal tract of type 2 diabetic mice, prolong the digestion process of carbohydrate, effectively reduce the decomposition of hepatic glycogen and reduce postprandial blood sugar. After a certain amount of food containing oat beta-glucan is ingested, the blood sugar is obviously reduced, and the blood sugar and insulin level are obviously related to the relative molecular mass size and the taking dosage of the beta-glucan. Soluble dietary fiber in the oat delays gastric emptying by reducing the gastric emptying rate, so that the glucose absorption rate of the small intestine is reduced, and the glucose tolerance curve becomes gentle; meanwhile, the dietary fiber can also inhibit the action of beta-amylase on starch, prolong the time of the enzyme acting on the starch and slow down the release of glucose. During the digestion process, the addition of the dietary fiber also increases the viscosity of intestinal juice and slows down the diffusion of glucose; more importantly, the glucose absorption enhancer can also reversibly adsorb glucose, so that the effective concentration of the glucose in intestinal juice is reduced, and the glucose tolerance is remarkably improved. By taking the oat oligopeptide for a long time, the blood sugar level of a diabetic rat can be effectively reduced, the area under the blood sugar curve is reduced, and the oat oligopeptide has the auxiliary blood sugar reducing function. The oat oligopeptide can regulate blood sugar and prevent and treat complications by improving the oxidative stress level of the body.
The polyphenols in buckwheat are represented by rutin, and can remove active oxygen in human body, and the active oxygen can cause diabetes and induce damage to islet cells. The buckwheat protein can improve the activity of superoxide dismutase and can protect the function of islet beta cells by removing free radicals. The alkaline protease is adopted to extract the low molecular weight active peptide with the relative molecular mass of 100-1000U, and animal experiments show that the active peptide can effectively inhibit the in vitro lipid peroxidation reaction and has the function of reducing blood sugar of diabetes caused by alloxan. The buckwheat D-chiro-inositol has the obvious function of reducing fasting blood glucose for diabetic ICR mice and has the obvious function of reducing fasting blood glucose and postprandial blood glucose for diabetic patients.
The highland barley contains various phenolic compounds, such as ferulic acid, syringic acid, anthocyanin and the like, and the compounds exist in free state and combined state, are mostly enriched in bran and germ parts, and have the effects of reducing blood fat, reducing blood sugar and the like. The highland barley beta-glucan has the effects of reducing the concentration of postprandial blood sugar, insulin and C peptide and relieving the functional burden of islet beta-cells, can enhance postprandial satiety, and can improve the sugar tolerance and blood fat metabolism of a second meal. The highland barley can improve the insulin sensitivity and prevent and treat insulin resistance to a certain extent after being eaten for a long time.
Rhizoma Polygonati belongs to medicinal and edible Chinese medicinal materials, and has effects of invigorating spleen, moistening lung, promoting fluid production, and lowering blood sugar. The rhizoma Polygonati extract contains various alcohols, aldehydes, ketones, phenols, etc., and has polyphenol extraction amount (19.8 + -0.1) mg/g under the conditions of ethanol solution volume fraction of 70%, extraction time of 2.5h, extraction temperature of 70 deg.C, and material-liquid ratio of 1: 25. Performing 3 verification tests at 50 deg.C under the condition of liquid-to-material ratio of 52: 1 and extraction time of 2h, and averaging to obtain an average value, wherein the extraction rate of polyphenols per 100g rhizoma Polygonati is 1.07g, and the flash extraction method adopts ethanol concentration of 50%, material-to-liquid ratio of 1:20, extraction time of 35s, and extraction time of 2 times, and the extraction rate of polyphenols of rhizoma Polygonati is (0.4788 + -0.0023)%.
The kudzu root also belongs to a medicinal and edible traditional Chinese medicine and has the function of reducing blood sugar. The macroporous resin adsorption method is adopted, the adsorption temperature is 59 ℃, the adsorption time is 180min, the pH value is 6.0, and the average value of the total polyphenol extraction rate of 5 times of parallel experiments is 0.2623%. Puerarin in the polyphenol component can reduce the concentration of glucose in vivo, improve hyperglycemia and insulin resistance state, and protect pancreatic islet beta cells.
The yeast has high content of trace element chromium, and has auxiliary blood sugar lowering effect.
Therefore, the invention exerts the synergistic hypoglycemic effect through the comprehensive action of various bioactive substance groups. The quinoa is rich in protein, oat polypeptide, oat oligopeptide, buckwheat protein and the like in the oat have the effect of reducing blood sugar, the protein content and the utilization rate in a plurality of crops are high, the low GI value is realized, the quinoa is very suitable for being eaten by diabetics, and the blood sugar rising index can be reduced. The dietary fiber can achieve the effect of reducing glucose absorption by the body by increasing satiety and delaying food absorption, thereby achieving the purpose of reducing blood sugar. The oat and the highland barley are rich in beta-glucan, and can act synergistically, increase satiety, delay food absorption, and improve sugar tolerance and blood sugar level. The buckwheat flavone, the D-chiro-inositol, the phenolic compounds in the highland barley, the oat polyphenol, the quinoa ecdysone and the like have the effect of reducing blood sugar, can have the synergistic effect on the effect of reducing blood sugar under the synergistic effect of various bioactive substances, and has good effect on diabetes. Compared with the existing health food, the invention has the advantages of safety, high efficiency, good taste and no toxic or side effect.
Detailed Description
Example an animal experiment of the composition of the invention on the reduction of blood glucose in mice
1 animal and feed
SPF grade adult male C57BL/6J mice, body mass 22 + -2 g, license number SCXK (Kyoto) 2008-. The animal is bred in a barrier environment animal laboratory with the qualification number of SCXK (Jing) 2011-. Common feed and high fat feed (20% sucrose, 2.5% cholesterol, 10% lard, 1% sodium cholate, 66.5% basal feed)
2 instruments and reagents
A full-automatic biochemical analyzer (Shenzhen mairui biomedical electronics, ltd), a bai' ankang rapid glucometer, a disposable blood glucose test paper, an iMark enzyme-linked immunosorbent assay (Bio-rad, usa), a high-speed centrifuge (model 5424, Eppendorf, germany); an electronic analytical balance (AX120, shimadzu, japan), and the like.
Streptozotocin (Sigma, usa), insulin kit (tianjin shengda biotechnology limited).
3 method
3.1 preparing animal model, namely adaptively feeding 38C 57BL/6J male mice for 1 week, randomly extracting 6 mice as normal control groups, and feeding the mice with common feed; after the remaining 32 mice were fed with high-fat diet for 4 weeks, the group was fasted for 12 hours with Streptozotocin (STZ) injected intraperitoneally at 30 mg/kg. The common feed feeding group is injected with citric acid-sodium citrate buffer solution with the same volume at the same time. After 3d, blood sugar after fasting for 12h is detected, and fasting blood sugar larger than 11.1mmol/L is taken as the successful standard of diabetes molding.
3.2 grouping and administration methods: 6 of the normal control groups; randomly selecting some mice from mice successfully modeled after diabetes and grouping the mice: model group 6, metformin group 6, compound grain group 6. The compound feed prepared by compound grain group administration: cleaning quinoa, highland barley, buckwheat and oat, and draining, wherein according to 45 parts by weight of quinoa, 20 parts by weight of oat, 10 parts by weight of highland barley, 10 parts by weight of buckwheat, 5 parts by weight of buckwheat bran, 5 parts by weight of buckwheat germ, 3 parts by weight of rhizoma polygonati and 2 parts by weight of radix puerariae, putting the mixture into a crusher, and crushing the mixture for 30-40 seconds at 30000-39000 revolutions/min to obtain mixed powder. It was mixed with deionized water to make strips about 6 cm long and about 1.5 cm in diameter. Placing into a microwave oven, baking with 80 firepower for 3min, and turning over every 1 min during heating. Cooling to room temperature after baking to obtain the prepared food, and storing in a refrigerator at-20 deg.C. The normal control group mice were fed with 6 g/mouse of the normal diet per day, the model group and the metformin group were fed with 6 g/mouse of the high-fat diet per day, and the compound grain group was fed with 3 g/mouse of the high-fat diet and the compound diet per day. The dosage of the metformin group is 0.15g/kg, and the model group and the normal group are administered with purified water with the same amount for 8 weeks.
3.3 specimen collection and index detection, blood is taken from mouse eyeball, and serum is reserved for detecting Fasting Blood Glucose (FBG) and Fasting Insulin (FINS).
4 statistical treatment
SPSS 22.0 is adopted to carry out statistical analysis on experimental data, metering data are expressed by x +/-s, pairing t test is adopted for front and back comparison, variance analysis is adopted for inter-group comparison, one-factor variance analysis is adopted for inter-group comparison, an LSD method is adopted for pairwise comparison, and the difference is considered to have statistical significance when P is less than 0.05.
5 results
5.1 comparison of FBG levels in groups of mice
TABLE 1 comparison of levels of pre-and post-intervention FBG in each group of mice (x + -s table)
Figure BDA0002475532090000091
P < 0.05, compared to normal group; and the delta P is less than 0.05, and is compared with a model group.
Table 1 the results show that: before and after intervention, compared with a normal group, the serum FBG level of the mouse in the model group is obviously increased, and the difference has statistical significance (P is less than 0.05), which indicates that the model is successfully made; compared with the model group, the serum FBG level of the mice of the compound grain group and the metformin group is obviously reduced, and the difference has statistical significance (P is less than 0.05). The compound cereal powder is suggested to reduce fasting blood glucose of type 2 diabetic mice.
5.2 comparison of FINS (fasting blood insulin) levels in groups of mice
TABLE 2 FINS level comparison of groups of mice (x. + -. s table)
Figure BDA0002475532090000101
P < 0.05, compared to normal group; and the delta P is less than 0.05, and is compared with a model group.
The results in table 2 show that compared with the normal group, the serum FINS of the model group is obviously reduced, and the difference has statistical significance and accords with the pathological characteristics of insulin secretion reduction of type 2 diabetes; compared with the model group, the FINS of the compound grain group and the FINS of the metformin group are increased, and the difference has statistical significance. The compound cereal powder is suggested to promote insulin secretion of type 2 diabetic mice, thereby regulating carbohydrate metabolism.
EXAMPLE two clinical study of the composition of the invention for lowering blood glucose in humans
1. Study subjects: 10 patients with type 2 diabetes were recruited in this study, divided into a compound grain group (the specific composition and dosage ratio were the same as in example one, mixed powder was directly taken) and a buckwheat group, and brought into the standard: the fasting blood glucose of the T2DM diagnostic standard which accords with the Chinese T2DM prevention and treatment guideline (2017 edition) is more than or equal to 7.0mmol/L, and the glycosylated hemoglobin is more than or equal to 6.3%. Exclusion criteria: patients with gestational diabetes or type 1 diabetes; ② patients with serious primary diseases of other organs such as heart, liver, kidney, lung, brain, etc.; ③ patients with acute complications such as diabetic ketosis, infection, etc.
2. Grouping experiments: after the patients with type 2 diabetes signed an informed consent, the cured compound cereal powder and buckwheat powder were respectively eaten for 12 weeks on the basis of the conventional treatment, and the changes of blood sugar and glycated hemoglobin before and after the treatment were respectively observed.
3. The eating method comprises the following steps: the 2 groups of patients took one bag (about 35g per bag) of compound cereal powder and buckwheat powder before three meals a day respectively, and took the mixture after being mixed with warm water into paste, and the intake of staple food can be reduced according to circumstances.
4. As a result: blood glucose and glycated hemoglobin changes before and after 12 weeks
After 12 weeks of treatment, the fasting blood sugar and the glycosylated hemoglobin of the buckwheat group patients have no statistical significance before treatment; the average value of fasting blood sugar of the compound grain group patients is reduced by 1.71mmol/L, the average value of glycosylated hemoglobin is reduced by 1.14%, and the average value is statistically significant (P is less than 0.05) compared with that before treatment.
TABLE 3 statistics of fasting plasma glucose in each group before and after treatment
Figure BDA0002475532090000111
Note: p < 0.05 at week 12 of treatment compared to pre-treatment.
TABLE 4 statistics of glycated hemoglobin for each group before and after treatment
Figure BDA0002475532090000112
Note: p < 0.05 at week 12 of treatment compared to pre-treatment.
5. And (4) conclusion:
compared with a simple buckwheat group, the compound grains are used for adjuvant therapy of type 2 diabetes patients, so that the fasting blood sugar and the glycosylated hemoglobin value of the patients can be effectively reduced, and the blood sugar control condition of the patients can be improved.
EXAMPLE three methods of preparing the compositions of the invention
Cleaning quinoa, highland barley, buckwheat and oat, and draining, wherein according to 45 parts by weight of quinoa, 20 parts by weight of oat, 10 parts by weight of highland barley, 10 parts by weight of buckwheat, 5 parts by weight of buckwheat bran, 5 parts by weight of buckwheat germ, 3 parts by weight of rhizoma polygonati and 2 parts by weight of radix puerariae, putting the mixture into a crusher, and crushing the mixture for 30-40 seconds at 30000-39000 revolutions/min to obtain mixed powder. It was mixed with deionized water to make strips about 6 cm long and about 1.5 cm in diameter.
The above examples are for illustrative purposes only, and the scope of the present invention is not limited thereto. Modifications will be apparent to those skilled in the art and the invention is limited only by the scope of the appended claims.

Claims (10)

1. A health food composition comprises grain rich in plant polyphenol and sterol, Chinese medicinal materials, and optionally yeast.
2. The health food composition of claim 1, wherein the cereal comprises one or more of quinoa, oat, buckwheat, highland barley, buckwheat bran, and buckwheat germ.
3. The health food composition of claim 1 or 2, wherein the Chinese herbal medicine comprises one or both of rhizoma Polygonati and radix Puerariae.
4. The health food composition of claim 2, wherein the grains comprise 30-60 parts by weight of quinoa, 10-20 parts by weight of oat, 10-20 parts by weight of buckwheat bran, and 5-10 parts by weight of buckwheat germ.
5. The health food composition of claim 2, wherein the grains comprise 45 parts by weight of quinoa, 20 parts by weight of oat, 10 parts by weight of highland barley, 10 parts by weight of buckwheat, 5 parts by weight of buckwheat bran, and 5 parts by weight of buckwheat germ.
6. The health food composition of claim 3, wherein the traditional Chinese medicine comprises 2-5 parts by weight of rhizoma Polygonati, 2-5 parts by weight of radix Puerariae, and optionally 1-2 parts by weight of yeast.
7. The health food composition of claim 6, comprising quinoa 30-60 parts, oat 10-20 parts, buckwheat bran 10-20 parts, buckwheat germ 5-10 parts, sealwort 2-5 parts, kudzu 2-5 parts, and optionally yeast 1-2 parts.
8. The health food composition of claim 6, comprising quinoa 30-50 parts by weight, highland barley 10-20 parts by weight, oat 10-20 parts by weight, buckwheat bran 5-10 parts by weight, buckwheat germ 5-10 parts by weight, polygonatum rhizome 2-5 parts by weight, kudzu root 2-5 parts by weight, and optionally yeast 1-2 parts by weight.
9. Use of the health food composition of any one of claims 1-8 for ameliorating diabetes.
10. Use of the health food composition of any one of claims 1-8 for assisting in lowering blood glucose.
CN202010362704.9A 2020-04-30 2020-04-30 Health food composition rich in plant polyphenol and sterol Pending CN113575928A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010362704.9A CN113575928A (en) 2020-04-30 2020-04-30 Health food composition rich in plant polyphenol and sterol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010362704.9A CN113575928A (en) 2020-04-30 2020-04-30 Health food composition rich in plant polyphenol and sterol

Publications (1)

Publication Number Publication Date
CN113575928A true CN113575928A (en) 2021-11-02

Family

ID=78237165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010362704.9A Pending CN113575928A (en) 2020-04-30 2020-04-30 Health food composition rich in plant polyphenol and sterol

Country Status (1)

Country Link
CN (1) CN113575928A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114145457A (en) * 2021-12-10 2022-03-08 黑龙江飞鹤乳业有限公司 Hypoglycemic composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103416663A (en) * 2013-08-28 2013-12-04 山东卫康生物医药科技有限公司 Whole-grain complete-nutrition formulation food for diabetics
CN104431741A (en) * 2015-01-14 2015-03-25 张桂英 Cereal conditioning porridge and making method and application thereof
CN106135791A (en) * 2015-03-25 2016-11-23 天津阿尔发保健品有限公司 A kind of blood sugar lowering spy's meals ready-to-eat cereal powder of enriched nutritive
CN106420955A (en) * 2016-11-29 2017-02-22 汤臣倍健股份有限公司 Traditional Chinese medicine composition with blood glucose reduction assistance effect, preparation method and product of traditional Chinese medicine composition
CN109123351A (en) * 2018-07-25 2019-01-04 刘德平 A kind of special doctor's food and preparation method with hyperglycemia population generation meal regulatory function
CN110367449A (en) * 2019-08-20 2019-10-25 肖诗禄 A kind of preparation method of the steady sugared herbal cuisine for improving hyperglycemia and its a steady sugared herbal cuisine steamed bread of corn

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103416663A (en) * 2013-08-28 2013-12-04 山东卫康生物医药科技有限公司 Whole-grain complete-nutrition formulation food for diabetics
CN104431741A (en) * 2015-01-14 2015-03-25 张桂英 Cereal conditioning porridge and making method and application thereof
CN106135791A (en) * 2015-03-25 2016-11-23 天津阿尔发保健品有限公司 A kind of blood sugar lowering spy's meals ready-to-eat cereal powder of enriched nutritive
CN106420955A (en) * 2016-11-29 2017-02-22 汤臣倍健股份有限公司 Traditional Chinese medicine composition with blood glucose reduction assistance effect, preparation method and product of traditional Chinese medicine composition
CN109123351A (en) * 2018-07-25 2019-01-04 刘德平 A kind of special doctor's food and preparation method with hyperglycemia population generation meal regulatory function
CN110367449A (en) * 2019-08-20 2019-10-25 肖诗禄 A kind of preparation method of the steady sugared herbal cuisine for improving hyperglycemia and its a steady sugared herbal cuisine steamed bread of corn

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114145457A (en) * 2021-12-10 2022-03-08 黑龙江飞鹤乳业有限公司 Hypoglycemic composition

Similar Documents

Publication Publication Date Title
Luo et al. Hypoglycemic effects and modulation of gut microbiota of diabetic mice by saponin from Polygonatum sibiricum
Amin et al. Effect of Carnitine and herbal mixture extract on obesity induced by high fat diet in rats
CN102406860B (en) Composition for preventing and treating diabetes, and preparation method and use thereof
Ma et al. Anti-diabetic effects of soluble and insoluble dietary fibre from deoiled cumin in low-dose streptozotocin and high glucose-fat diet-induced type 2 diabetic rats
Shi et al. Bioactive compounds from Polygonatum genus as anti-diabetic agents with future perspectives
CN100356867C (en) Black edible fungus health food and its preparation method
CN101234142B (en) Mulberry series health care functional beverage for auxiliary reduction of blood sugar
JP2016505533A (en) Composition for maintaining intestinal microbiota equilibrium, process for producing the composition, and use of the composition
CN101116487A (en) Instant nutritive gruel having a function of stabilizing body blood sugar after meal and method for preparing the same
CN104431741A (en) Cereal conditioning porridge and making method and application thereof
CN103285231A (en) Medicine composition for diabetes adjunctive therapy and preparation method thereof
CN103156108A (en) Fortified food for preventing and treating diabetes mellitus and hypertension diseases
KR20090021644A (en) A carbohydrate and lipid absorption inhibitory nelumbo composition and its manufacturing process thereof
CN113575928A (en) Health food composition rich in plant polyphenol and sterol
WO2022021780A1 (en) Medicated diet and dietary therapy composition for type 2 diabetes and preparation method therefor
CN110731509A (en) A health product containing prebiotics for lowering blood sugar and blood lipid, and its preparation method
CN115252737A (en) Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease, preparation method and application
CN113826887A (en) Blood pressure and blood fat reducing and blood sugar reducing nutrition powder, plant extract and application thereof
EP3978009A1 (en) Traditional chinese medicine increase and decrease prescription for preventing/treating metabolic syndrome and complications thereof
CN109259086B (en) Constipation-adjustable nutritional rice and preparation method thereof
Prativadibhayankaram et al. Anti-diabetic activity of triphala fruit extracts, individually and in combination, in a rat model of insulin resistance
CN109430721A (en) A kind of wheat embryo composition and preparation method thereof with hypoglycemic effect
JP2006257018A (en) Antiobestic agent, medicine and beverage or food
Nnadi et al. Effects of formulated unripe plantain and millet dietary feeds in Alloxan-induced diabetic albino rats
CN109567175A (en) A kind of auxiliary hyperglycemic, compound Siraitia grosvenorii functional food of reducing blood lipid and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20211102

RJ01 Rejection of invention patent application after publication